Two C04 oligopeptides, corresponding to residues (37-53) and (37-55) of the V1 domain of C04, which recent structural studies propose as the most likely binding site of HIV-1 gp120, have been chemically synthesized by solid-phase techniques, modified by the addition of two side-chain protected cysteines at both termini and purified by HPLC. Their ability to inhibitthe infectivity of human immunodeficiency virus type 1 (HIV-1) (HTLV-IIIB, RF and GBB' strains) in different cell lines was monitored by the production of progeny virus, p24 and reverse transcriptase activity in the culture supernatants and by electron microscopy. The results indicated that the peptides inhibited HIV-1 infectivity in a dose-dependent fashion without any detectable cytotoxicity.
Introduction
CD4 is a glycoprotein which is associated with class II molecules in the recognition process between T cells and antigen-presenting cells (Doyle and Strominger, 1978; Gay et al., 1987; Sleckman et al., 1987; Robey and Axel, 1990) . CD4 is also the receptor for human immunodeficiency virus (HIV) and plays a key role in determining the cell tropism of the virus and in promoting some of its cytopathic effects both in vitro and in vivo (Dalgleish et al., 1984; Klatzman et al., 1984; McDougal et al., 1986; Maddon et al., 1986) . HIV binds to CD4 through the N-terminus of gp120, the virus envelope glycoprotein (Peterson and Seed, 1988; Clayton etal., 1988; Mizukami etal., 1988). CD4 is essential for virus infection as shown by the susceptibility to HIV infection of CD4+ cells and by transfection experiments whereby expression of this molecule in non-permissive human cells allowed replication of HIV. For these reasons CD4 has been viewed as a potential therapeutic tool to block de novo infection.
Previous reports have already shown that the soluble/ anchor-minus form of CD4 molecule (SCD4) is effective in inhibiting HIV infectivity in vitro, and clinical trials are ongoing (Traunaker et al., 1989) . Attempts are also being made to improve the pharmacokinetic profile of CD4 by genetic or chemical fusion to Ig fragments and to increase its therapeutic potential by conjugation with toxin (Chaudhary et sl., 1988; Capon et al., 1989) . Recently, a few studies have been carried out to evaluate the anti-HIV-1 effectiveness of synthetic oligopeptides representative of different portions ofthe receptor molecule (Jameson et al., 1988) . Conflicting results have emerged in relation to the psrtioular amino acid (aa) sequence responsible for the antiviral activity of the peptides and the role of the chemical modifications thereupon. In this regard, Arthos et al. (1989) have shown that mutations within the region of, approximately, residues 41-52, homologous to the complementarity-determining region 2 (CDR2) of immunoglobulin light chains, affect gp120-CD4 interactions. On the other hand, a number of different authors (Ufson et al., 1988; Nara et al., 1989; Hayashi et al., 1989) have shown that peptides belonging to the CDR3 domain of CD4, namely fragments spanning residues 81-92, are capable of blocking HIV-1 syncytium formation and infectivity. The retention of benzyl-protecting groups on Cys-84 and Glu-85 was found to be important for biological activity. In the present paper we report on the anti-HIV-1 activity of two selectively modified synthetic CD4 peptides in comparison to the activity exhibited by the soluble CD4 molecule.
Results

Peptide synthesis
As shown in Table 1 , peptides A and B encompass the amino acid sequences of the CD4 CDR2 region. Products were >98% pure as determined by high-performance liquid chromatography (HPLC)in different solvent systems and showed the expected amino acid composition. The primary structure was confirmed by Edman degradation.
Both A and B contain two protected cysteines deliberately inserted at the C and N-termini to allow disulphide bond formation and the formation of a loop structure, for conformational restriction experiments. Since, at the present stage of the study, both cysteines are blocked by acetoamido methylation (Acm groups), these peptides are free to move and to accommodate themselves into the putative natural interaction site. Peptide C is a synthetic control peptide representative of the C-terminal region of horse heart cytochrome C, sequence (81-104), unrelated to A and B,.which was synthesized, purified and characterized as reported for the CD4-derived peptides.
Inhibition of HIB-1 growth in cultured cells
The data are presented in Fig. 1 as an example of a dose-response curve and are summarized in Table 2 as the peptide ED so values for different pairs of viral strains and cell lines. It appears that the two CD4 peptides, like sCD4 ( Fig. 1a,b ), inhibit virus yield in a dose-dependent manner, when added to cultures directly or after a short pre-incubation with the virus suspension. ED so values were of the order of 1Of-Lg/ml (5f-LM) irrespective of the virus strain and the cell type used. These values may represent a s~ight over-estimation, since the peptide content in the sample was 80% by weight as determined by amino acid ·analysis. sCD4 was more effective (Table 2) , by at least one order of magnitude in terms of weight (0.3 f-Lg/ml) and two in molar terms (50nM), with an ED so close to that already reported (Arthos et sl., 1989) . Production of both p24 ( Fig. 2) and RT (not shown) was dramatically decreased in HIV-1 III B-infected H9 cells treated with the peptides compared with untreated cells. Inhibition was dependent on oliqopeptide concentration and reached maximum at 10 f-Lg/ml. Electron microscopy did confirm the measurements of the biological parameters of viral replication (not shown). No antiviral activity was exhibited by the unrelated horse heart cytochrome C peptide, which was used as an internal negative control.
Assay of cell cytotoxicity
Peptides A and B at 200 f-Lg/ml were virtually devoid of cytotoxicity as shown by the growth curve,of treated and untreated H9 cells over a time period (3 days) allowing at least three cycles of replication ( Fig. 3) . Signs of cytotoxicity only appeared at doses exceeding 500 f-Lg/ml (50-fold higher than those at which antiviral activity was observed). The limited amounts of pure reagents did not permit an ED so value to be obtained.
Discussion
Recent reports have appeared in the literature about the effectiveness of CD4 oligopeptides as inhibitors of HIV-1 replication. However, the definition of the biologically active amino acid sequence is still controversial, since the functional and structural properties of both the CD4 molecule and the HIV glycoprotein have not been dissected. In particular, it is not totally clear as yet which of the different external regions of CD4 is the most crucial for gp120 binding. Homoloque-scanmnq mutagenesis studies (Landau et el., 1988; Clayton et sl., 1988; Arthos et al., 1989; Lamarre et et., 1989; Sattentau et al., 1989) have indicated that a relevant role might be played by the CDR2-like domain, in the stretch from amino acids 40-50. An approach using alanine-scanning mutagenesis, on the other hand, has produced evidence that mutations within the CD3-like region cause disruptions of gp120 CD4 interactions at least as pronounced as those mediated by mutations in the CDR2-like domain (Ashkenazi et al., 1990) .The importance ofthis domain (amino acids 37-52), as~he most exposed N-terminal region of CD4 which is probably involved in the gp 120 recognition process, has al., 1989). Differences in activity observed could reflect the specific requirement for a certain degree of structural complexity by our peptides, and support the view that the gp 120-binding site of CD4 consists of several discontinuous segments (Ashkenazi et al., 1990) . On this basis, it could also be explained Why CD4 oligopeptides representative of a different portion of the CD4 molecule (i.e. amino acids 81-92) possess antiviral activity (Nara et al., 1989) .
Dose-response effects and lack of cytotoxicity by A and B would suggest a kind of selectivity. The molecular basis for it could reside on the specific sequence we employed and its relation with gp120, but an interference with other processes, such as exocytosis (Nara et al., 1989) , or with molecular targets different from the viral glycoprotein, cannot be excluded. Since A and B are endowed with a certain degree of mobility, they could freely adapt themselves to a complementary region of interaction. The alternative possibility that they could give rise to tertiary structures, although still under study, seems quite remote. Therefore, if the block of HIV infectivity is operating at the a. Progeny production was assayed by syncytia formation in newly infected cells. CCID 5 0 values were determined according to Reed and Muench (1938) . b. CC is the amino acid (81-104) sequence of heart horse cytochrome C. NO, not done. been further highlighted by very recent crystallographic data (Wang et al., 1990; Ryu et al., 1990) . It therefore appears that this sequence ought to be part of a newly designed peptide to confer it with an anti-HIV-1 activity. For the above considerations we have synthesized two oligopeptides spanning the sequences (37-53) and (37-55), which are called A and B. In view of conformational studies which are underway and of possible mobility restriction, two side-chain-blocked cysteine residues were linked to the two termini of both peptides. Experiments performed with three different pairs of viral strains and cell lines, using a back titration assay and measuring p24 and RT, show that both A and Bare effective in inhibiting HIV-1 replication. The two oligos have a comparable activity which is, however, much lower (virtually two orders of magnitude in molar term) than the one exhibited by the whole CD4 molecule. The addition of residue (54-55) in B is apparently not crucial for antiviral activity (Jameson et al., 1988) .A totally unrelated synthetic peptide of similar M r representative of the C-terminal region of horse heart cytochrome C was devoid of any effect. The inhibition of HIV-1 infectivity is, thus, in line with previous results using either longer peptides (25-58) (Jameson et al., 1988) dicyclohexylcarbodiimide and introduced as hydroxybenzotriazole esters. Each residue incorporation was followed by a 'capping' cycle using acetic anhydride. At the end of the synthesis, the peptide-resin was suspended in 500 fLl of anisole and treated with 10ml of HF. The reaction mixture was stirred at O°C for 1h, the HF was evaporated under vacuum and the solids were triturated with 50ml of 10% AcOH. After lyophilization the peptides were purified by ion-exchange chromatography using a Protein Pack SP 5PW Waters column (0.8 x 7.5 cm) with different gradients of solution B (10mMNa2HP042H20, pH 6) at a flow rate of 1ml/min. Each peptide was then further purified by reversephase C 18 HPLC on a Delta Pack, 15 fL, 300A Waters column (7.8 x 30cm) using 0.1% trifluoroacetic acid with a gradient of acetonitrile containing 0.1% trifluoroacetic acid. A purity >98% for each peptide was determined by analytical chromatography on a Resolve 5 u, 1OOA Waters column (3.9 x 15 cm). The amino acid composition of the synthesized peptides, after hydrolysis with 6 MHCI for 22 h at 110°C, was determined with a Carlo Erba automated amino acid analyser AAA3A28 and gave the expected cornpostlon. Soluble CD4 was obtained from Microgenesis (West Haven, Cl). level of the gp12D-CD4 interaction, the role the peptides play has to be akin to that of a simple ligand, for they can not mimic, in classical terms, the function of a receptor structure.
From our investigation we cannot rule out the possibility that other CD4 regions may interfere with HIV infectivity, possibly through gp120 binding.
As for the design of more powerful anti-HIV-1 peptides, our study would indicate that a certain degree of structural complexity which accounts for long-range effects and protein folding is clearly needed to grant the active CD4 region the potential for a high-affinity binding to gp120.
Dissection of the three-dimensional structure of both the HIV-1 glycoprotein and CD4, which is currently ongoing, will certainly contribute to a more rational peptide design.
Materials and Experimental procedures
Chemicals
Starting resins, Bee-protected amino acids in preloaded cartridges and all solid-phase synthesis reagents were supplied by Applied Biosystems (Foster City, CAl.
Synthesis, hydrofluoric acid (HF) cleavage and purification of peptides
Viruses and cells H9, C8166 and JM cells were routinely grown in RPMI-1640 medium supplemented with 10-20% foetal calf serum (FCS), antibiotics and L-glutamine. The HIV-1 HTLV-IIIB, RF and GB8 strains were titrated by syncytia formation, essentially as described previously (Arthos et al., 1989) .
Assay of antiviral activity
H9, C8166 and JM cells were originally seeded in 25-cm flasks at a concentration of 3 x 10 5 cells/ml in 12ml final volume. Cultures were infected with the HIV-12 HTLV-IIIB, RF and GB8 strains, respectively, at a virus multiplicity of 10 CCID so. Before being added to cell cultures, virus suspensions were incubated with different concentrations of CD4 and oligopeptides for 5 min at room temperature. After the absorption period, cells were incubated at 3rC for 5-7 days. Supernatants were then tested for progeny virus (Reed and Muench, 1938) . ED so values were obtained, essentially as described elsewhere (Palu et al., 1986a) , by relating the progeny virus production in the newly infected cells to the peptide concentration. In another set of experiments, H9 cells were infected with HIV-1 IIIB in the presence of the synthetic oligopeptides and viral growth was directly assessed by syncytia formation, electron microscopy, p24 (ELISA; DuPont, Willmington, DE) and reverse transcriptase (Rl) titration, as reported previously (Filice et al., 1988) .
Assembly of the polypeptide chains was carried out by step-wise techniques on solid support by using an Applied Biosystem 431A automated peptide synthesizer starting with 0.5 mmol of Boc-Cys(Acm)-MBHA-resin. The following side-chain protection was used: acetamidomethyl (Acm) for cysteine, benzyl for serine and threonine, p-chlorocarbobenzoxy for lysine, cyclohexyl for aspartic acid. Boc removal was accomplished by using one 2-min wash and one 20-min treatment with 65% trifluoroacetic acid in methylene chloride. Boc protected amino acids were activated by Assay of cell cytotoxicity H9 cells were seeded at a concentration of 100000 cells/ml in RPMI-1640 supplemented with 20% FCS in the presence of increasing concentrations of oligopeptides and incubated for a period of 72h. At this time-point viable cells were counted by trypan blue staining in a conventional haemocythometer (Palu etal., 1986b) .
